Extension usage examples:
Here's how our browser extension sees the article:
Cancer cell-expressed BTNL2 facilitates tumour immune escape via engagement with IL-17A-producing γδ T cells - PubMed
Source: pubmed.ncbi.nlm.nih.gov
Article summary:
1. Butyrophilin-like protein 2 (BTNL2) is a potent suppressor of the anti-tumour immune response.
2. Antibody-mediated blockade of BTNL2 attenuates tumour progression in multiple in vivo murine tumour models, resulting in prolonged survival of tumour-bearing mice.
3. High BTNL2 expression in several human tumour samples from highly prevalent cancer types negatively correlates with overall patient survival, suggesting that BTNL2 is a potential target for cancer immunotherapy.
Article analysis:
The article provides an overview of the role of Butyrophilin-like protein 2 (BTNL2) as a suppressor of the anti-tumour immune response and its potential as a target for cancer immunotherapy. The authors present evidence from both mouse and human studies to support their claims, including data from multiple in vivo murine tumour models demonstrating that antibody-mediated blockade of BTNL2 attenuates tumour progression and prolongs survival of tumour-bearing mice, as well as data showing high BTNL2 expression in several human tumours which negatively correlates with overall patient survival.
The article appears to be reliable and trustworthy, providing evidence to support its claims and presenting both sides equally. The authors have provided detailed information about their methods and results, allowing readers to assess the validity of their findings. Furthermore, they have acknowledged potential limitations such as the need for further research into the mechanisms by which BTNL2 facilitates immune escape and how it can be targeted therapeutically.